StreetAlpha.app
Home › Stocks › MLTX

MoonLake Immunotherapeutics (MLTX)

Healthcare
$11.25
▼ −4.09%
LAST CLOSE · NOV 17

MoonLake Immunotherapeutics is a Swiss biotech developing SLK, an experimental Nanobody treatment for inflammatory skin and joint diseases. It last closed at $11.25 on Nov 17, down 4.09% on the day.

AI Auto Pilots
Is MLTX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$273.5M
EPS (diluted)
−$3.66
Free cash flow
−$244.0M
Valuation
Market cap
$957.5M
85.1M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$379.7M
At Sep 30
Debt
$100.0M
At Sep 30
Shareholder equity
$381.6M
Shares outstanding
85.1M
At Nov 1
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$4.5M−$4.5MFY2021FY2022: −$50.0M−$50.0MFY2022FY2023: −$36.0M−$36.0MFY2023FY2024: −$118.9M−$118.9MFY2024FY2025: −$227.3M−$227.3MFY2025

From MLTX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated MLTX in the past 90 days, not enough for a consensus
Average 12-month target
$50.00
▲ 344.4% upside

Based on 1 analyst who set a price target on MLTX in the past 90 days. The average target is $50.00, with a high of $50.00 and a low of $50.00, compared with the last close of $11.25.

Low $50.00Avg $50.00High $50.00
Blue marker: last close $11.25
Highest target$50.00
Average target$50.00
Lowest target$50.00
Latest rating changes
HC Wainwright & Co.Reiterated
Oct 5Buy$50
HC Wainwright & Co.Target raised
Aug 13Buy$45 → $50
HC Wainwright & Co.Reiterated
Jul 20Buy$45
Leerink PartnersMaintained
Jul 1Buy$29
Wolfe ResearchUpgrade
Mar 23Buy$24
DateFirmActionRatingPrice target
Oct 5HC Wainwright & Co.ReiteratedBuy$50
Aug 13HC Wainwright & Co.Target raisedBuy$45 → $50
Jul 20HC Wainwright & Co.ReiteratedBuy$45
Jul 1Leerink PartnersMaintainedBuy$29
Mar 23Wolfe ResearchUpgradeBuy$24
Loading…

Technical Analysis

MLTX · as of the Nov 17 close · updated after every close
Moving sideways

The stock is 6% below its 20 day and 4% below its 50 day average. It is 44% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 45). The nearest support is the Pivot S1 at $10.88, and the nearest resistance the Pivot at $11.30.

Short trendNeutral
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 7.5%/day
Key levels
$23.2952 week high+107.0%
$16.22200 day average+44.2%
$14.73100 day average+30.9%
$12.95Swing high (Oct 29)+15.1%
$11.9720 day average+6.4%
$11.7450 day average+4.4%
$11.67Pivot R1+3.7%
$11.30Pivot+0.4%
$11.25Last close
$10.88Pivot S1−3.3%
$10.66Swing low (Nov 5)−5.2%
$9.4652 week low−15.9%
Indicators
RSI (14)44.78Middle of its rangeNeutral
MACD0.10Above its signal lineBullish
Stochastic35.9Middle of its rangeNeutral
ADX (14)23.9Weak trend
Williams %R-81.9Oversold below −80, overbought above −20Oversold
CCI (20)-86.2Oversold below −100, overbought above 100Neutral
Rate of change−3.9%Change over 10 sessionsBearish
ATR (14)$0.84Typical daily range, 7.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for MLTX

What happened before

See how MLTX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow MLTX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How MLTX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in MLTX in the last 90 days.

Loading…

See today’s whale options flow across the market →

MLTX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲97 buying vs 82 selling
  • ▼Held by funds -0.8 pts
  • ▼Funds holding -5
  • ▲Superinvestors: 3 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding169174−2.9%
In funds' top 1023−33.3%
Held by funds85.5%86.3%−0.8 pts
New / increased32 / 6540 / 72−13.4%
Reduced / sold out45 / 3745 / 16+34.4%
Put/call ratio0.550.23+137.3%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See MLTX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MLTX is in one of them and how their past MLTX trades turned out.

MLTX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered MLTX in an article yet. Here's the latest on the wider market.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a biotechnology company based in Zug, Switzerland, that is developing SLK, an experimental medicine for inflammatory skin and joint diseases. SLK is a Nanobody, a small antibody-like molecule, that blocks two related immune signals called IL-17A and IL-17F. The company is testing SLK in conditions such as hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis and palmoplantar pustulosis, for patients under the care of skin and joint specialists. It does not yet have an approved product.

Headquarters
Zug, Switzerland